Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial

Abstract Background The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk for myocardial infarction has not been fully characterized. Methods This study comprised prespecified and post-hoc analyses of the EMPA-REG OUTCOME trial in which 7020 people with type 2 diabetes (T...

ver descrição completa

Detalhes bibliográficos

Principais autores:	David Fitchett, Bernard Zinman, Silvio E. Inzucchi, Christoph Wanner, Stefan D. Anker, Stuart Pocock, Michaela Mattheus, Ola Vedin, Søren S. Lund
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-07-01
coleção:	Cardiovascular Diabetology
Assuntos:	Diabetes mellitus Type 2 Myocardial infarction Sodium-glucose transporter 2 inhibitors
Acesso em linha:	https://doi.org/10.1186/s12933-024-02328-6
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!